Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Tyme TechnologiesAVEO PharmaceuticalsGalectoCorMedixXeris Pharmaceuticals
SymbolNASDAQ:TYMENASDAQ:AVEONASDAQ:GLTONYSEAMERICAN:CRMDNASDAQ:XERS
Price Information
Current Price$1.54$6.46$5.97$9.37$3.97
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.31.21.71.21.6
Analysis Score3.53.53.53.53.2
Community Score2.42.64.42.52.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.01.7
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$9.50$17.80$14.00$19.30$13.00
% Upside from Price Target516.88% upside175.54% upside134.51% upside105.98% upside227.46% upside
Trade Information
Market Cap$200.86 million$175.26 million$150.81 million$356.29 million$237.27 million
Beta0.941.4N/A2.712.22
Average Volume10,376,3132,368,27931,3141,207,4142,661,002
Sales & Book Value
Annual RevenueN/A$28.80 millionN/A$280,000.00$2.72 million
Price / SalesN/A6.09N/A1,272.4587.23
CashflowN/A$0.46 per shareN/A$0.25 per shareN/A
Price / CashN/A14.08N/A37.85N/A
Book Value$0.15 per share$0.92 per shareN/A$0.92 per share$0.53 per share
Price / BookN/A7.02N/A10.187.49
Profitability
Net Income$-22,000,000.00$9.39 millionN/A$-16,430,000.00$-125,580,000.00
EPS($0.17)$0.61N/A($0.89)($4.81)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-483.99%N/A-10,214.42%-2,037.97%
Return on Equity (ROE)-192.69%-103.66%N/A-86.52%-435.27%
Return on Assets (ROA)-111.68%-48.01%N/A-70.16%-91.81%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.34%N/AN/A4.49%
Current Ratio3.62%4.29%N/A8.45%6.86%
Quick Ratio3.62%4.29%N/A8.40%6.65%
Ownership Information
Institutional Ownership Percentage13.01%33.70%N/A25.91%69.33%
Insider Ownership Percentage25.51%4.50%N/A5.00%6.12%
Miscellaneous
Employees18492330180
Shares Outstanding130.43 million27.13 million25.26 million38.02 million59.77 million
Next Earnings Date5/19/2021 (Estimated)4/29/2021 (Estimated)7/5/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Insider Sells $40,700.00 in StockXeris Pharmaceuticals, Inc. (NASDAQ:XERS) Insider Sells $40,700.00 in Stock
americanbankingnews.com - April 13 at 8:16 PM
Before You Invest, Make Sure You Check This Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) AnalysisBefore You Invest, Make Sure You Check This Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Analysis
stocksregister.com - April 13 at 7:05 PM
How is the Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) performance outlook for the coming months?How is the Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) performance outlook for the coming months?
marketingsentinel.com - April 13 at 2:00 PM
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Could Soar to Much Higher Prices in Coming MonthsXeris Pharmaceuticals, Inc. (NASDAQ:XERS) Could Soar to Much Higher Prices in Coming Months
marketingsentinel.com - March 29 at 9:51 AM
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) shares surges 11.46% in a week – but can it keep rising?Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) shares surges 11.46% in a week – but can it keep rising?
marketingsentinel.com - March 25 at 9:50 AM
Need To Know: Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Insiders Have Been Buying SharesNeed To Know: Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Insiders Have Been Buying Shares
finance.yahoo.com - March 23 at 3:03 PM
Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)
openpr.com - March 16 at 2:20 PM
Xeris Pharmaceuticals (NASDAQ:XERS) Rating Increased to Hold at Zacks Investment ResearchXeris Pharmaceuticals (NASDAQ:XERS) Rating Increased to Hold at Zacks Investment Research
marketbeat.com - March 13 at 7:45 AM
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Analysts Are Cutting Their Estimates: Heres What You Need To KnowXeris Pharmaceuticals, Inc. (NASDAQ:XERS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
nasdaq.com - March 11 at 12:54 PM
Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct OfferingXeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
finance.yahoo.com - March 11 at 7:53 AM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Xeris Pharmaceuticals, Inc. (XERS) and Encourages Investors to Contact the FirmBronstein, Gewirtz & Grossman, LLC Announces Investigation of Xeris Pharmaceuticals, Inc. (XERS) and Encourages Investors to Contact the Firm
finance.yahoo.com - March 10 at 2:44 PM
Why Xeris Pharmaceuticals Is Trading Lower TodayWhy Xeris Pharmaceuticals Is Trading Lower Today
msn.com - March 9 at 1:09 PM
Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue EstimatesXeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 9 at 1:09 PM
Xeris Pharmaceuticals: Q4 Earnings SnapshotXeris Pharmaceuticals: Q4 Earnings Snapshot
miamiherald.com - March 9 at 8:08 AM
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent HighlightsXeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
finance.yahoo.com - March 9 at 8:08 AM
Earnings Outlook for Xeris PharmaceuticalsEarnings Outlook for Xeris Pharmaceuticals
finance.yahoo.com - March 8 at 2:54 PM
XERS Jan 2022 1.500 callXERS Jan 2022 1.500 call
uk.finance.yahoo.com - March 8 at 9:51 AM
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021
finance.yahoo.com - March 2 at 10:24 AM
Dont Just Sit There, Work Those TradesDon't Just Sit There, Work Those Trades
finance.yahoo.com - February 20 at 2:45 PM
Xeris: Recent Success Warrants A Closer LookXeris: Recent Success Warrants A Closer Look
seekingalpha.com - February 19 at 8:26 AM
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference PresentationsXeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
finance.yahoo.com - February 18 at 9:34 AM
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS): Is Breakeven Near?Xeris Pharmaceuticals, Inc. (NASDAQ:XERS): Is Breakeven Near?
finance.yahoo.com - February 12 at 6:10 PM
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged ...Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged ...
businesswire.com - February 12 at 7:44 AM
XERS Stock Price Increases Over 20% Pre-Market: Why It HappenedXERS Stock Price Increases Over 20% Pre-Market: Why It Happened
pulse2.com - February 12 at 7:44 AM
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes MellitusXeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
finance.yahoo.com - February 12 at 7:44 AM
Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?
finance.yahoo.com - February 11 at 3:11 PM
DateCompanyBrokerageAction
6/29/2020Tyme TechnologiesCanaccord GenuityReiterated Rating
5/21/2020Tyme TechnologiesHC WainwrightReiterated Rating
3/17/2021AVEO PharmaceuticalsSVB LeerinkBoost Price Target
11/9/2020AVEO PharmaceuticalsStifel NicolausInitiated Coverage
9/2/2020AVEO PharmaceuticalsPiper SandlerReiterated Rating
5/29/2020AVEO PharmaceuticalsRobert W. BairdBoost Price Target
11/4/2019AVEO PharmaceuticalsPiper Jaffray CompaniesLower Price Target
3/28/2019AVEO PharmaceuticalsNational SecuritiesInitiated Coverage
2/4/2019AVEO PharmaceuticalsB. RileyReiterated Rating
3/22/2021GalectoCredit Suisse GroupLower Price Target
11/23/2020GalectoBank of AmericaInitiated Coverage
2/17/2021CorMedixNeedham & Company LLCInitiated Coverage
9/29/2020CorMedixJMP SecuritiesInitiated Coverage
9/21/2020CorMedixTruistInitiated Coverage
12/6/2018CorMedixRoth CapitalReiterated Rating
11/27/2020Xeris PharmaceuticalsMizuhoReiterated Rating
6/30/2020Xeris PharmaceuticalsRoyal Bank of CanadaReiterated Rating
7/16/2018Xeris PharmaceuticalsJefferies Financial GroupInitiated Coverage
(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.